Prague, Czech Republic
Prague, Czech Republic

Time filter

Source Type

News Article | March 3, 2017
Site: www.PR.com

Cyrex Laboratories Adds Unique Expertise with Two New Team Members Cyrex Laboratories continues to attract the best and brightest in immunology testing with additions of Dr. Mark Engelman and Michelle Clark. Phoenix, AZ, March 03, 2017 --( Dr. Engelman joins the Cyrex team as Clinical Consultant to provide his expert guidance on test result interpretation, clinical relevance of results, and possible treatment protocols. He will also speak on behalf of Cyrex at industry conferences and educational events as an authority on functional medicine. Dr. Engelman is a practicing physician specializing in internal medicine, with advanced degrees in stem cell and functional medicine. He is Founder and President of the Engelman Health Institute and has a 23-year tenure as the Director of St. Joseph's Medical Center emergency department in Phoenix, Arizona. Dr. Engelman also has the distinction of having been standby physician for two American presidential administrations, President of the Maricopa County American Heart Association, Chief Physician for the Arizona Boxing Commission; and is Founder and CEO of AmeriMed American Hospitals in Mexico. “The old paradigm for how we evaluate and respond to a patient’s health is on the way out,” said Dr. Engelman. “Medicine is becoming more personalized, and advances in immunology testing are a prime example of the shift toward a patient-specific, more holistic approach - and Cyrex Labs is at the forefront of this movement. I look forward to working with the Cyrex team to help patients learn more about how their immune systems respond to the environment and the foods they consume.” Michelle Clark has been tapped as Director of Sales to help execute Cyrex’s strategic growth plan. Clark’s 25-year focus on high-complexity laboratory testing will be an extraordinary asset in developing client relationships as she educates healthcare providers about the value of the Cyrex System. Clark is a business strategist, marketing expert, speaker and writer with extensive leadership and management experience. Prior to joining Cyrex, Clark was Director of Sales and Marketing at Alletess Medical Laboratory, where she was instrumental in the transformation of that company into an international allergy laboratory with sustainable and profitable growth. She is a Board Advisor for the International College of Integrative Medicine and a member of the American Academy of Environmental Medicine, where she serves on the Exhibitor Committee. Clark is also a current member of the American College of Nutrition. “Cyrex leads the industry in quality standards for laboratory testing. By sharing with healthcare providers the extra steps Cyrex takes to ensure the accuracy of its testing, I hope to help the business fully realize its growth potential,” said Clark. Physicians and other licensed healthcare professionals, as well as patients, interested in learning more about Cyrex and its unique approach to assessing immune reactivity and autoimmunity are encouraged to visit www.joincyrex.com for additional information. About Cyrex Laboratories Cyrex is a clinical immunology laboratory specializing in functional immunology and autoimmune reactivity. Cyrex offers multi-tissue antibody testing for the early detection and monitoring of today’s complex autoimmune conditions. Cyrex develops innovative testing arrays through continuous collaboration with leading experts in medical research and clinical practice. Cyrex technology is built on four pillars of excellence, including the antigen purification system, optimized antigen concentration, antigen-specific validation and parallel testing technology. Cyrex is a CLIA licensed laboratory based in Phoenix, Arizona and holds a Medical Device Establishment License in Canada. Phoenix, AZ, March 03, 2017 --( PR.com )-- Cyrex Laboratories, a leading clinical laboratory specializing in functional immunology and autoimmunity, continues to attract the highest caliber professionals to the organization. With the addition of Dr. Mark Engelman, M.D., FSCM, ABAARM, FAARM, and Michelle Clark, MBA, Cyrex further reinforces its team’s expertise in functional medicine and laboratory business development.Dr. Engelman joins the Cyrex team as Clinical Consultant to provide his expert guidance on test result interpretation, clinical relevance of results, and possible treatment protocols. He will also speak on behalf of Cyrex at industry conferences and educational events as an authority on functional medicine.Dr. Engelman is a practicing physician specializing in internal medicine, with advanced degrees in stem cell and functional medicine. He is Founder and President of the Engelman Health Institute and has a 23-year tenure as the Director of St. Joseph's Medical Center emergency department in Phoenix, Arizona. Dr. Engelman also has the distinction of having been standby physician for two American presidential administrations, President of the Maricopa County American Heart Association, Chief Physician for the Arizona Boxing Commission; and is Founder and CEO of AmeriMed American Hospitals in Mexico.“The old paradigm for how we evaluate and respond to a patient’s health is on the way out,” said Dr. Engelman. “Medicine is becoming more personalized, and advances in immunology testing are a prime example of the shift toward a patient-specific, more holistic approach - and Cyrex Labs is at the forefront of this movement. I look forward to working with the Cyrex team to help patients learn more about how their immune systems respond to the environment and the foods they consume.”Michelle Clark has been tapped as Director of Sales to help execute Cyrex’s strategic growth plan. Clark’s 25-year focus on high-complexity laboratory testing will be an extraordinary asset in developing client relationships as she educates healthcare providers about the value of the Cyrex System.Clark is a business strategist, marketing expert, speaker and writer with extensive leadership and management experience. Prior to joining Cyrex, Clark was Director of Sales and Marketing at Alletess Medical Laboratory, where she was instrumental in the transformation of that company into an international allergy laboratory with sustainable and profitable growth. She is a Board Advisor for the International College of Integrative Medicine and a member of the American Academy of Environmental Medicine, where she serves on the Exhibitor Committee. Clark is also a current member of the American College of Nutrition.“Cyrex leads the industry in quality standards for laboratory testing. By sharing with healthcare providers the extra steps Cyrex takes to ensure the accuracy of its testing, I hope to help the business fully realize its growth potential,” said Clark.Physicians and other licensed healthcare professionals, as well as patients, interested in learning more about Cyrex and its unique approach to assessing immune reactivity and autoimmunity are encouraged to visit www.joincyrex.com for additional information.About Cyrex LaboratoriesCyrex is a clinical immunology laboratory specializing in functional immunology and autoimmune reactivity. Cyrex offers multi-tissue antibody testing for the early detection and monitoring of today’s complex autoimmune conditions. Cyrex develops innovative testing arrays through continuous collaboration with leading experts in medical research and clinical practice. Cyrex technology is built on four pillars of excellence, including the antigen purification system, optimized antigen concentration, antigen-specific validation and parallel testing technology. Cyrex is a CLIA licensed laboratory based in Phoenix, Arizona and holds a Medical Device Establishment License in Canada. Click here to view the list of recent Press Releases from Cyrex Laboratories


The medical tourism industry in Malaysia is booming, which contributed to the fierce competition among the leading market players. Because the market is heading towards its maturity, a majority of the prominent enterprises are looking to offer dynamic changes in their services and products to keep reporting sustainable growth. Despite the presence of a large number of companies, the Medical Tourism Market in Malaysia still exhibits a high degree of consolidation, with the leading players holding the crux of the market, finds Transparency Market Research (TMR) in a new report. Some of the leading companies exhibiting a strong presence in the Malaysia medical tourism market are KPJ Healthcare Berhad, Prince Court Medical Centre, IJN Health Institute, Sunway Medical Centre, and Island Hospital. These institutions are focusing on emerging dominant by expanding their geographic footprint. Enhancing their foreign customer base has therefore become a key tactic for enterprises looking to establish a stronghold in the Malaysia medical tourism market. According to TMR, the medical tourism market in Malaysia is forecast to expand a whopping 30.05% CAGR between 2016 and 2024. At this incredible pace, the market will reach US$3.5 bn by the end of 2024, from a valuation of US$424.96 mn in 2016. Approximately 36.6% of medical tourists availed dental treatments in 2016, making it a leading market segment. Besides this, the market also witnessed considerably high demand in aesthetics/cosmetic surgery procedures and health screening segments. Low cost of medical services, compared to the same offered in developed economies of North America and Europe is the chief factor luring foreign medical tourists to Malaysia. Besides this, persistent government activities to boost the sector will synergize the country's medical tourism industry. "With the rising influx of medical tourists from MENA and neighboring countries, the medical tourism market in Malaysia is poised to surge exponentially in the coming years," said a lead TMR analyst. The accelerated pace of gains witnessed in the medical tourism market in Malaysia is contributed by excellent macro-economic factors such as the increasing government programs promoting medical tourism, excellent transport facilities, and decent recuperation facilities. For instance, to boost medical tourism, the Malaysian government offers varied tax incentives, especially on the revenue generated from foreign patients. "In 2009, the government offered tax exemption of 50% on revenues earned from foreign patients, which was later increased to a whopping 100% by the end of 2010," said a lead TMR analyst. Moreover, medical tourism is considered as one of the 12 national key economic areas (NKEAs) in Malaysia, which is a chief driver of the market. On the downside, medical inflation recorded in 2015 and a slight drop in the number of medical travelers could have an adverse influence on the market. Besides this, the market is already witnessing challenges from low revenue generated per patient, soaring healthcare costs, and the mounting burden on Malaysia's healthcare system. Nevertheless, Malaysia is positioned as a preferred destination for medical travelers, which has potentiated the country's medical tourism market. This review is based on a TMR PR, titled "Medical Tourism Market - Malaysia Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024." The report segments the Malaysia medical tourism market as: Regenerative Medicine Market (Bone and Joint) (Technology - Stem Cell Therapy, Biomaterial and Tissue Engineering; Application - Bone Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, Autogenic Products and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 Ophthalmology Diagnostics and Surgical Devices Market (Optical Coherence Tomography, Echography, Corneal Topographers, Specular Microscopes, Cataract, Refractive, Glaucoma and Vitreoretinal Surgery Devices) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2016 - 2024 Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.


News Article | October 31, 2016
Site: www.prnewswire.com

SHENZHEN, China, Oct. 31, 2016 /PRNewswire/ -- The first World Medical Robotics Conference, hosted by Medical Robotics Society (MRS) and organized by ROBO Health Institute, was held in Shenzhen on Oct 29th -30th, 2016. The event was chaired by Yangsheng Xu, dean of Chinese University...


Global Medical Aesthetics Market Forecast to 2024 – New Report by Data Bridge Market Research Global Medical Aesthetic Market, By Product Type (Aesthetic Laser Devices, Energy Devices, Skin Tightening and Body Contouring Devices, Aesthetic Implants, Facial Aesthetic Devices), By Applications (Anti Aging and Wrinkles, Facial & Skin Rejuvenation, Vascular Lesions, Body shaping & cellulite, Breast Enhancement, Scars, Pigment Lesions, Reconstructive Surgery, Tattoo Removal, Psoriasis & Vitilgo, Skin Surgery), End-User, Distribution Channel, Geography – Industry Trends and Forecast to 2024 Dallas, TX, February 18, 2017 --( The global medical aesthetic devices market is segmented on the basis of product type, application, end-user, distribution channel and geography. On the basis of product type the market is segmented into Aesthetic Laser devices which is further sub divided into Fractional Carbon Dioxide Laser Resurfacing, Ablative Skin Resurfacing Devices, Non-Ablative Fractional Laser Skin Resurfacing; Energy Devices which is further segmented into Electrocautery, Electrosurgery, Cryosurgery, Laser surgery, Microwave, Harmonic scalpel. Based on application the market is segmented into food and beverage testing, pharmaceutical, industrial, environmental testing, geological sciences, petrochemical, academics and, others. On the basis of application the market is segmented into anti aging and wrinkles, facial & skin rejuvenation, vascular lesions, body shaping & cellulite, breast enhancement, scars, pigment lesions, reconstructive surgery, tattoo removal, hair removal, psoriasis & vitilgo, skin tightening and others. Based on end user the market is segmented into hospitals, dermatology clinics, cosmetic centers, medical spas & beauty center. Request for sample pages: https://databridgemarketresearch.com/reports/global-medical-aesthetics-market/ Based on geography the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and Middle East and Africa. The report of this market covers data for countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, and South Africa. Read more: https://databridgemarketresearch.com/medical-aesthetics-market-poised-grow-8-6/ The key players operating in this market are Allergan plc, Neograft Technologies Inc, BTL Aesthetics, Galderma S.A., Thermi, Merz Pharma Gmbh & Co, Surgical Specialties Corporation, Suneva Medical, Venus concept, Valeant Pharmaceuticals International, Sientra Inc, Cynosure Inc, Revance Therapeutics Inc, Zeltiq Aesthetics Inc, Dynatronics Corporation, EternoGen Aesthetics, GC Aesthetics, Obagi Skin Health Institute, Dermatology Associates, Alma Lasers GmbH, Cutera Inc, Cynosure Inc, Ellman International Inc, Genesis Biosystems Inc, Iridex Corporation, PhotoMedex Inc, Sciton Inc, Smith & Nephew Healthcare Pvt. Ltd., Solta Medical Corporate, Syneron Medical Ltd, Laboratories Vivacy, Prollenium Medical Technologies among others. About Data Bridge Market Research: Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Dallas, TX, February 18, 2017 --( PR.com )-- The Global medical aesthetics market is expected to reach USD 16.1 billion by 2024 from USD 8.33 billion in 2016, at a CAGR of 8.6% in the forecast period 2017 to 2024. The new market report contains data for historic years 2014 & 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.The global medical aesthetic devices market is segmented on the basis of product type, application, end-user, distribution channel and geography.On the basis of product type the market is segmented into Aesthetic Laser devices which is further sub divided into Fractional Carbon Dioxide Laser Resurfacing, Ablative Skin Resurfacing Devices, Non-Ablative Fractional Laser Skin Resurfacing; Energy Devices which is further segmented into Electrocautery, Electrosurgery, Cryosurgery, Laser surgery, Microwave, Harmonic scalpel. Based on application the market is segmented into food and beverage testing, pharmaceutical, industrial, environmental testing, geological sciences, petrochemical, academics and, others.On the basis of application the market is segmented into anti aging and wrinkles, facial & skin rejuvenation, vascular lesions, body shaping & cellulite, breast enhancement, scars, pigment lesions, reconstructive surgery, tattoo removal, hair removal, psoriasis & vitilgo, skin tightening and others.Based on end user the market is segmented into hospitals, dermatology clinics, cosmetic centers, medical spas & beauty center.Request for sample pages: https://databridgemarketresearch.com/reports/global-medical-aesthetics-market/Based on geography the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and Middle East and Africa. The report of this market covers data for countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, and South Africa.Read more: https://databridgemarketresearch.com/medical-aesthetics-market-poised-grow-8-6/The key players operating in this market are Allergan plc, Neograft Technologies Inc, BTL Aesthetics, Galderma S.A., Thermi, Merz Pharma Gmbh & Co, Surgical Specialties Corporation, Suneva Medical, Venus concept, Valeant Pharmaceuticals International, Sientra Inc, Cynosure Inc, Revance Therapeutics Inc, Zeltiq Aesthetics Inc, Dynatronics Corporation, EternoGen Aesthetics, GC Aesthetics, Obagi Skin Health Institute, Dermatology Associates, Alma Lasers GmbH, Cutera Inc, Cynosure Inc, Ellman International Inc, Genesis Biosystems Inc, Iridex Corporation, PhotoMedex Inc, Sciton Inc, Smith & Nephew Healthcare Pvt. Ltd., Solta Medical Corporate, Syneron Medical Ltd, Laboratories Vivacy, Prollenium Medical Technologies among others.About Data Bridge Market Research:Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Click here to view the list of recent Press Releases from Data Bridge Market Research


News Article | December 13, 2016
Site: www.businesswire.com

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix International N.V. (NASDAQ:OFIX), a diversified, global medical device company, today announced that Alexis V. Lukianov has been named to its Board of Directors. Mr. Lukianov’s appointment expands the Board to 10 directors, 9 of whom are independent directors. With more than 30 years’ experience, and an extensive background in orthopedics, Mr. Lukianov has held senior executive positions with companies such as Medtronic SofamorDanek and Smith and Nephew Orthopaedics, where he was the director of a business unit that brought limb lengthening technology to the United States from Russia. He was the founder of and served as the Chairman of the Board and CEO of BackCare Group, Inc., a spine physician practice management company, and from 1999-2015, Mr. Lukianov served as the Chairman and CEO at NuVasive, Inc. “We are pleased that Alex Lukianov will join our Board of Directors. As a senior experienced executive in the med-tech industry, Alex will be a valued strategic participant as we continue to focus on developing our growth opportunities,” said Ron Matricaria, Chairman of the Board. An entrepreneur, Mr. Lukianov has served on a variety of public, private and not-for-profit boards including the Volcano Corporation, the California Health Institute, BIOCOM, and the Medical Device Manufacturers Association (MDMA). Orthofix International N.V. is a diversified, global medical device company focused on improving patients’ lives by providing superior reconstructive and regenerative orthopedic and spine solutions to physicians worldwide. Headquartered in Lewisville, TX, the company has four strategic business units that include BioStim, Biologics, Extremity Fixation and Spine Fixation. Orthofix products are widely distributed via the company’s sales representatives, distributors and subsidiaries. In addition, Orthofix is collaborating on research and development activities with leading clinical organizations such as Brown University, Sinai Hospital of Baltimore, Cleveland Clinic, Texas Scottish Rite Hospital for Children and the Musculoskeletal Transplant Foundation. For more information, please visit www.orthofix.com.


News Article | February 21, 2017
Site: www.prweb.com

The Colorado Health Access Fund of The Denver Foundation is now accepting funding proposals from organizations and collaboratives working to increase access to behavioral health care and improve health outcomes for high-need populations across Colorado. Approximately $5 million is available for projects and programs that increase health outcomes across the state, particularly in rural communities. Applications are due Friday, March 10, and grants will be awarded in August 2017. Applicants must register with The Denver Foundation’s online application system by Wednesday, March 1. Complete guidelines are available online. The intent of the Colorado Health Access Fund is to help ensure that health care services are equitably available to all Coloradans with high health needs by distributing funds to organizations that serve people in rural, urban, and suburban areas. The fund will prioritize programs that serve those who are low-income and/or experiencing homelessness; have multiple chronic or acute health conditions; and/or lack health insurance coverage, have inadequate coverage, or have significant barriers to accessing coverage. General operating support is also available. Resources will be directed in four project areas: According to a 2014 analysis of the health care landscape conducted by the Colorado Health Institute and commissioned by The Denver Foundation, 15 of the 21 Colorado Health Statistic Regions included mental/behavioral health as a top local public health priority. Furthermore, mental and behavioral health care was cited as a community priority in every community dialogue conducted by CHI. Discussions with health and community foundations identified access to mental health and substance abuse as the most pressing issues statewide. Thus, the Colorado Health Access Fund is focused on increasing access to behavioral health treatment. In 2015, the Colorado Health Access Fund distributed nearly $2.2 million to 28 grantees across Colorado. A summary of the activities and impact of the first cohort of grantees is available here. Overall, the Colorado Health Access Fund seeks to: For more information and to apply, please visit http://denverfoundation.org/community/page/colorado-health-access-fund. About The Colorado Health Access Fund The Colorado Health Access Fund was created in 2015 with an anonymous $40 million gift as a Field of Interest fund at The Denver Foundation. The intent of the fund is to support programs/activities that generally increase access to health care and strive to improve health outcomes for populations in Colorado with high health care needs. The fund will help to ensure health care services are equitably available to all Coloradans with high health needs by distributing the funds to organizations throughout the state. The Colorado Health Access Fund will distribute approximately $5 million per year through 2022. About The Denver Foundation The Denver Foundation is a community foundation that inspires people and mobilizes resources to improve life in Metro Denver. In 2015, the Foundation and its donors awarded more than $97 million in grants. The Denver Foundation has three roles: stewarding an endowment to meet current and future needs for Metro Denver, working with community leaders to address the core challenges that face the community, and managing more than 1,000 charitable funds on behalf of individuals, families, and businesses. For more information, visit http://www.denverfoundation.org.


News Article | February 15, 2017
Site: www.prweb.com

InDemand Interpreting, a technology-enabled language services performance improvement company and a leading video remote interpreting (VRI) provider within Healthcare, announced a webinar: “Telebehavioral Health and Interpreting Services for Underserved Populations: 21st Century Behavioral Health.” This webinar is hosted in partnership with the Telebehavioral Health Institute, an organization that offers telebehavioral health professional training for clinicians from more than 55 countries. This webinar will address the critical issue of providing Behavioral Health to LEP (limited English proficient) patients and increasing access and availability to achieve better outcomes. New care models and payment structures are evolving to answer provider concerns. In this webinar, participants will gain an understanding of: The featured speaker for this webinar is Marlene M. Maheu, Ph.D., donned the “telepsychology visionary,” and executive director for Telebehavioral Health Institute. Dr. Maheu began delivering telehealth services in 1994 and she is now a consultant, researcher, author, trainer, keynoter and company founder. Casey Zanetti, Vice President of Marketing for InDemand Interpreting, will lead the discussion on understanding LEP populations and their impact on behavioral health, laws that require language access for LEP populations and technologies that can assist with this growing need. InDemand Interpreting connects health care professionals to medically trained and qualified interpreters 24 hours a day, seven days a week, in more than 200 languages, including American Sign Language (ASL). “We are delighted to partner with the Telebehavioral Health Institute to conduct a webinar that will benefit healthcare organizations nationwide,” said Cecil Kost, Chairman and CEO of InDemand Interpreting. “Video remote interpreting offers an accessible, cost effective and reliable language services solution to meet the needs of telebehavioral health for use in all healthcare settings.” For more information about the webinar and to register, visit: https://www.indemandinterpreting.com/upcoming-events/webinar-21st-century-behavioral-health-technology-can-help-increase-access-underserved-populations/ About InDemand Interpreting InDemand Interpreting was founded in 2007 with the vision of ensuring that every patient receives the highest quality healthcare, regardless of language, cultural background or disability. By delivering the most experienced medical interpreters and highest quality video technology InDemand Interpreting provides doctors, nurses and clinicians the language access they need to provide the best possible care. Visit InDemand at http://www.indemandinterpreting.com


News Article | December 23, 2016
Site: www.prnewswire.co.uk

Real World Evidence of PU Reduction Using Early-Detection Technology - An Attack on the UK's £2.1bn Health Problem MANCHESTER, England and LOS ANGELES, Dec. 23, 2016 /PRNewswire/ -- Using technology adapted from NASA's Mars lander as part of a large-scale bedsore reduction program, over half of the 13 participating hospitals were able to eliminate the occurrence of new bedsores completely; an additional 3 hospitals achieved reductions ranging from 11% to 90%. Nurses dramatically cut bedsore occurrence by detecting damage developing under patients' skin early enough to intervene and reverse the damage. This marks a breakthrough in prevention of the chronic condition costing the UK £2.1bn annually, which claimed the life of Superman actor Christopher Reeve. Bruin Biometrics ("BBI LLC"), which manufactures the early detection technology known as the SEM Scanner, enlisted 13 hospitals (including 10 NHS England Trusts) to participate in a novel Pressure Ulcer Prevention Program (PURP) incorporating SEM Scanner into existing care pathways for pressure ulcer prevention. The findings from over 1200 patients scanned are the most comprehensive real-world evidence that this early detection technology enables nurses to prevent bedsores before they break through the skin, a conclusion that upends the prevailing view that bedsores cannot be diagnosed and treated until they have caused visible and irreversible damage to the skin's surface. "These data challenge existing practice that looks for visual changes to skin to initiate bedsore intervention," BBI CEO Martin Burns said. "Scientific findings show that by the time damage is visible, it is far too late. Early detection changed the prognosis for millions of cancer survivors. A proactive approach to 'Act Before Red' is consistently doing the same for bedsores, on a large scale, across independent sites." "We reduced pressure ulcers in the ward concerned to zero during our Scanner trial – an achievement that, if we rolled out across our hospital, we estimate could save our hospital nearly £600,000 and release 1,420 hours of nurse productivity annually," said Glenn Smith, a tissue viability and nutrition senior clinical nurse specialist/patient safety lead at St. Mary's Hospital, part of the NHS Trust on the Isle of Wight, which has a large elderly population at risk for bedsores due to immobility. "In our pilot program, which included over 200 patients, we reduced bedsore incidence by 90%," said Rose Raizman, nurse practitioner, enterostomal therapist and pressure ulcer prevention at Scarborough and Rouge Hospital in Ontario, Canada. "SEM Scanner allows the clinician to 'visualise pathology' below the skin level before it becomes apparent at the surface, and should be used as the standard of care for pressure ulcer prevention." "The vast majority of nurses participating in our Scanner program said the device provided valuable clinical information," added Parker Moss, chief technology and transformation officer at Virgin Care, which experienced a 95 percent drop in the bedsore rate during an evaluation of the device at Farnham Community Hospital in Surrey, where it provides services to the NHS. SEM Scanner is a wireless non-invasive handheld device that assesses sub-epidermal moisture, or SEM, an indicator of early-stage damage beneath the skin surface as much as 10 days earlier than visual inspection by nurses. SEM Scanner was conceived by Barbara Bates-Jensen, a wound care expert and professor at the University of California at Los Angeles (UCLA), and adapted from seismology technology used on NASA's Mars landing craft to interrogate beneath the planet's surface.  Professor Bates-Jensen, Dr. Majid Sarrafzadeh, and Dr. William J. Kaiser, co-director of the UCLA Wireless Health Institute and a former engineer at Jet Propulsion Laboratories, partnered with BBI to adapt the space technology into the SEM Scanner. Bedsores, also known as pressure ulcers, are chronic wounds to the skin and tissue that often develop in patients who are immobile. Bedsores commonly lead to infection and death. In fact, bedsores kill more people annually than any form of cancer except lung cancer. There are nearly 500,000 bedsore cases annually in the UK. Until now, diagnosis has relied on visual inspection by nurses, which is subjective and which can only identify bedsores once visible damage to the skin has already begun. With early-detection, experts believe that over 80% of early-stage pressure ulcers can be prevented. "We've borrowed NASA's concept of 'Seeing the Unseen' to develop the first clinically-proven method for detecting unseen bedsores and alerting healthcare practitioners in real time when they begin to form under the skin," said Rachael Lester, BBI VP of Product. "With early detection, clinicians can initiate treatment before chronic damage develops. More and more clinicians are using the SEM Scanner and finding that they can overcome avoidable PUs, proving that ZERO is no longer Mission: Impossible." Real-world evaluation data presented by St. Mary's Hospital (Improved Patient Safety with Use of the SEM Scanner) and Virgin Care (Chasing Zero. Results from a New Pressure Ulcer Prevention Bundle) at the Wounds UK annual conference November 14-16 in Harrogate and are now being released publicly for the first time. About Bedsores Bedsores, also known as pressure ulcers, are a common medical problem that can lead to pain, disfigurement, infection and death. Pressure ulcers are an area of localized damage to the skin and underlying tissue – usually around an area of bony prominence, such as the sacrum, coccyx, heels, and hips – that results from pressure involving shear and/or friction. Across Europe and the United States, it is estimated that 18%-25% of patients in both acute care and long-term care settings suffer from pressure ulcers, disproportionately impacting the elderly and patients with limited mobility. There are some 2.5 million pressure ulcer cases annually in the European Union, and nearly 500,000 in the United Kingdom, which spends £2.1bn, or 4% of the NHS budget, on the condition. In the U.S., some 2.5 million Americans develop pressure ulcers annually in acute care facilities, and 60,000 Americans die annually from pressure ulcer complications such as cancer, sepsis, cellulitis, and MRSA. About BBI  Bruin Biometrics LLC, a pioneer in biometric-sensor based medical devices, is committed to the development of point-of-care diagnostic solutions for early detection and monitoring of chronic, preventable conditions. The company's first product is the SEM Scanner, a hand-held non-invasive device that assesses sub-epidermal moisture, a biomarker which has been found to detect early-stage pressure ulcers as much as 10 days earlier than visual observation. Pressure ulcers affect approximately 25% of acute care hospital and long-term care patients – typically the elderly and immobile. SEM Scanner is CE Mark approved and is currently in full commercial launch in the EU and Canada. SEM Scanner is not currently for sale in the United States. BBI is also developing OrthoSonos, a non-invasive device for real-time orthopaedic joint monitoring and assessment of prosthetic implant failure; and P02M, the first device for monitoring tissue oxygenation at a specific location in real time. P02M is initially being tested for continual monitoring of tissue and vascular viability in the feet of diabetics. Diabetes can cause peripheral artery disease and peripheral neuropathy, putting patients at risk for foot ulcers. BBI is based in Los Angeles and maintains a European office in Manchester, UK. For additional information, visit www.bruinbiometrics.com. Follow BBI on Twitter at https://twitter.com/bruinbiometrics.


News Article | December 9, 2016
Site: www.sciencemag.org

The National Institutes of Health (NIH) has tapped Major General James Gilman (retired), a longtime manager of military hospitals, to lead its troubled research hospital. A cardiologist, Gilman “has the kind of experience that we believe will serve us extremely well,” said NIH Director Francis Collins today at a meeting of his NIH Advisory Committee to the Director (ACD). As the center’s first CEO, Gilman will oversee management including patient safety and regulatory compliance at the hospital on NIH’s main campus in Bethesda, Maryland, starting early in 2017. He will work with former Clinical Center Director John Gallin, who is moving to the position of chief scientific officer (CSO) at the center. With more than 200 beds, the NIH Clinical Center is the world's largest hospital devoted to research. It specializes in studies of treatments for rare diseases and life-threatening disorders. But the discovery last year of fungal contamination in two vials of a drug produced in a facility at the center led to an investigation that found broader problems. Last spring, a working group of ACD delivered a scathing report that found patient safety had become “subservient to research demands.” The report recommended many reforms, including a new leadership structure like that at most hospitals with a CEO, chief operating officer, and chief medical officer. In May, NIH announced that Gallin’s leadership team would be replaced. The shakeup sparked an uproar among Clinical Center and other clinical research leaders at NIH, however. They defended the center’s patient safety record and said the working group’s report had “demonized” its leadership and “demoralized” employees. NIH seemed to step back slightly in August when it announced that Gallin would remain at the center as CSO and would also fill a new position overseeing all clinical research across NIH. The position is one of several steps NIH has taken to strengthen fragmented oversight of staff from the various institutes that conduct studies at the clinical center. Before retiring in 2013, Gilman oversaw several Army hospitals, most recently the U.S. Army Medical Research and Materiel Command in Fort Detrick, Maryland. He was executive director of Johns Hopkins Military & Veterans Health Institute in Baltimore, Maryland, until June. Gilman said at the meeting that he had “actively sought this job” because caring for patients who have agreed to be research subjects at NIH is “about as close as I could ever get in my professional career again” to caring for service members and their families. He is “gradually adapting to try to understand NIH culture and NIH-speak,” he added. NIH has been holding focus groups with staff on how to improve operations and shore up morale.


RESEARCH TRIANGLE PARK, N.C., Dec. 1, 2016 /PRNewswire/ -- The Soil Health Institute (SHI) and Datu Research today announced a $626,000 grant from the Walton Family Foundation to quantify the economic risks and rewards of soil health management systems used in farming. Management...

Loading Health Institute collaborators
Loading Health Institute collaborators